.
MergerLinks Header Logo

New Deal


Announced

Completed

Audax Private Equity and Linden Capital Partners-backed StatLab Medical Products completed the acquisition of CellPath.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private Equity

United Kingdom

Acquisition

Pharmaceuticals

health care

Friendly

medical products

Cross Border

Private

Majority

Single Bidder

Completed

Synopsis

Edit

Audax Private Equity and Linden Capital Partners-backed StatLab Medical Products, a developer and manufacturer of medical diagnostic supplies and equipment, completed the acquisition of CellPath, a UK-based manufacturer and supplier of products and services focused on the histology and cytology markets. Financial terms were not disclosed. "We have long respected CellPath for their well-earned reputation of delivering innovative products that solve problems for labs, and are proud to welcome them to the StatLab family of brands. Now paired with the strategic acquisition of UK-based equipment manufacturer Pyramid Innovation in 2021, CellPath’s established European market position and complementary portfolio will empower meaningful international growth in the histology sector,” Mike Karsonovich, StatLab CEO.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US